SG155205A1 - Interleukin-10 antibodies - Google Patents

Interleukin-10 antibodies

Info

Publication number: SG155205A1
Authority: SG; Singapore
Prior art keywords: antibodies; interleukin; methods; specific antibodies; compositions
Prior art date: 2003-11-10

Application number

SG200905318-2A

Other languages

English (en)

Inventor

Leonard G Presta

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-10

Filing date

2004-11-09

Publication date

2009-09-30

2004-11-09 Application filed by Schering Corp filed Critical Schering Corp

2009-09-30 Publication of SG155205A1 publication Critical patent/SG155205A1/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Virology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Microbiology (AREA)
Mycology (AREA)
Emergency Medicine (AREA)
AIDS & HIV (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)

SG200905318-2A 2003-11-10 2004-11-09 Interleukin-10 antibodies SG155205A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US51899903P	2003-11-10	2003-11-10

Publications (1)

Publication Number	Publication Date
SG155205A1 true SG155205A1 (en)	2009-09-30

Family

ID=34590335

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG200905318-2A SG155205A1 (en)	2003-11-10	2004-11-09	Interleukin-10 antibodies

Country Status (25)

Country	Link
US (5)	US20050101770A1 (de)
EP (4)	EP2128175A1 (de)
JP (4)	JP4762148B2 (de)
KR (3)	KR20120023858A (de)
CN (2)	CN100595212C (de)
AR (3)	AR046833A1 (de)
AT (1)	ATE440867T1 (de)
AU (2)	AU2004290044B2 (de)
CA (2)	CA2812856A1 (de)
CY (1)	CY1110557T1 (de)
DE (1)	DE602004022855D1 (de)
DK (1)	DK1694705T3 (de)
ES (1)	ES2329907T3 (de)
HR (1)	HRP20090517T1 (de)
IL (3)	IL175523A (de)
NO (1)	NO20062672L (de)
NZ (1)	NZ546632A (de)
PE (3)	PE20090047A1 (de)
PL (1)	PL1694705T3 (de)
PT (1)	PT1694705E (de)
RS (1)	RS51180B (de)
SG (1)	SG155205A1 (de)
SI (1)	SI1694705T1 (de)
WO (2)	WO2005047324A2 (de)
ZA (1)	ZA200603681B (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2429769C (en) *	2000-12-07	2016-04-26	Board Of Regents, The University Of Texas System	Methods of treatment involving human mda-7
WO2002057283A1 (en) *	2001-01-19	2002-07-25	Baylor College Of Medecine	Methods and compositions in breast cancer diagnosis and therapeutics
EP1490101A4 (de) *	2002-03-05	2006-09-20	Univ Texas	Verfahren zur verbesserung der immuninduktion mit mda-7
US8034790B2 (en) *	2003-12-01	2011-10-11	Introgen Therapeutics	Use of MDA-7 to inhibit pathogenic infectious organisms
JP4863885B2 (ja) *	2004-02-23	2012-01-25	ジンテーズゲゼルシャフトミトベシュレンクテルハフツング	骨ねじ
US20070281041A1 (en) *	2004-03-02	2007-12-06	Introgen Therapeutics, Inc.	Compositions and Methods Involving MDA-7 for the Treatment of Cancer
CA2597329C (en) *	2005-02-08	2016-10-11	Board Of Regents, The University Of Texas System	Compositions and methods involving mda-7 for the treatment of cancer
US20110104109A1 (en) *	2005-07-13	2011-05-05	Frank Bennett	Tetracyclic indole derivatives and their use for treating or preventing viral infections
LT1931710T (lt)	2005-08-31	2017-03-27	Merck Sharp & Dohme Corp.	Rekombinantiniai anti-il-23 antikūnai
WO2007092944A2 (en) *	2006-02-08	2007-08-16	Introgen Therapeutics, Inc.	Compositions and methods involving gene therapy and proteasome modulation
PL2066695T3 (pl) *	2006-09-05	2013-08-30	Lilly Co Eli	Przeciwciała przeciwko miostatynie
AR064333A1 (es)	2006-12-14	2009-04-01	Schering Corp	Anticuerpo anti-tslp de diseno
JP5211068B2 (ja) *	2006-12-22	2013-06-12	メルク・シャープ・アンド・ドーム・コーポレーション	Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体
CA2674831A1 (en)	2006-12-22	2008-11-13	Schering Corporation	5,6-ring annulated indole derivatives and methods of use thereof
MX2009006880A (es)	2006-12-22	2009-07-03	Schering Corp	Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
KR20090094846A (ko) *	2006-12-22	2009-09-08	쉐링 코포레이션	Ｃｄ200ｒ에 대한 항체
SG178804A1 (en)	2007-02-23	2012-03-29	Schering Corp	Engineered anti-il-23p19 antibodies
DK2426144T3 (en)	2007-02-23	2019-01-07	Merck Sharp & Dohme	Manipulated Anti-IL-23P19 Antibodies
NZ579251A (en)	2007-02-28	2012-06-29	Schering Corp	Engineered anti-il-23r antibodies
CA2697500A1 (en)	2007-08-29	2009-03-12	Schering Corporation	2,3-substituted azaindole derivatives for treating viral infections
ES2447543T3 (es) *	2007-08-29	2014-03-12	Merck Sharp & Dohme Corp.	Derivados de indol sustituidos y métodos de utilización de los mismos
EP2197842B1 (de) *	2007-08-29	2012-05-23	Schering Corporation	2,3-substituierte indolderivate zur behandlung von virusinfektionen
EP2222672B1 (de) *	2007-11-16	2013-12-18	Merck Sharp & Dohme Corp.	3-aminosulfonylsubstituierte indolderivate und verfahren zu deren anwendung
CA2705586A1 (en) *	2007-11-16	2009-05-22	Schering Corporation	3-heterocyclic substituted indole derivatives and methods of use thereof
WO2009152200A1 (en) *	2008-06-13	2009-12-17	Schering Corporation	Tricyclic indole derivatives and methods of use thereof
WO2010027488A2 (en) *	2008-09-04	2010-03-11	Vet Therapeutics, Inc.	Monoclonal antibodies
JP2012518404A (ja) *	2009-02-23	2012-08-16	グレンマーク・ファーマシューティカルズ・エスエー	Ｃｄ１９に結合するヒト化抗体及びその使用
CA2763140A1 (en)	2009-05-29	2010-12-02	Schering Corporation	Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
PT3023438T (pt)	2009-09-03	2020-05-08	Merck Sharp & Dohme	Anticorpos anti-gitr
AU2010324871A1 (en)	2009-11-25	2012-06-14	Merck Sharp & Dohme Corp.	Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
CN102711829B (zh) *	2009-11-30	2016-03-16	生物测试股份公司	治疗系统性红斑狼疮(sle)的人源化抗il-10抗体
CA2785488A1 (en)	2009-12-22	2011-07-21	Merck Sharp & Dohme Corp.	Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
US9433621B2 (en)	2010-02-18	2016-09-06	Merck Sharp & Dohme Corp.	Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2545060B1 (de)	2010-03-09	2015-11-25	Merck Sharp & Dohme Corp.	Kondensierte tricyclische silylverbindngen und verfahren zu deren verwendung zur behandlung von viralen krankheiten
ES2961381T3 (es)	2010-06-19	2024-03-11	Memorial Sloan Kettering Cancer Center	Anticuerpos anti-GD2
WO2012018534A2 (en)	2010-07-26	2012-02-09	Schering Corporation	Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EP2621279B1 (de)	2010-09-29	2018-04-04	Merck Sharp & Dohme Corp.	Kondensierte tetrazyklische derivate und verfahren zu ihrer verwendung zur behandlung von virenerkrankungen
EP2643352B1 (de) *	2010-11-23	2018-05-02	Glaxo Group Limited	Antigenbindende proteine zur bindung von oncostatin m (osm)
CA2858350A1 (en)	2011-01-14	2013-07-19	The Regents Of The University Of California	Therapeutic antibodies against ror-1 protein and methods for use of same
US9156872B2 (en)	2011-04-13	2015-10-13	Merck Sharp & Dohme Corp.	2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2696681B1 (de)	2011-04-13	2018-10-03	Merck Sharp & Dohme Corp.	2'-substituierte nukleosidderivate und verfahren zu ihrer verwendung zur behandlung von virenerkrankungen
CN102250243B (zh) *	2011-07-01	2013-08-28	华绍炳	抗白细胞介素-15抗体
WO2013033900A1 (en)	2011-09-08	2013-03-14	Merck Sharp & Dohme Corp.	Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en)	2011-09-14	2013-03-21	Merck Sharp & Dohme Corp.	Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
US9512405B2 (en)	2011-12-14	2016-12-06	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Non-enzymatic method for isolating human adipose-derived stromal stem cells
UA117466C2 (uk)	2012-12-13	2018-08-10	Мерк Шарп Енд Доме Корп.	СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US10167341B2 (en)	2013-03-15	2019-01-01	Memorial Sloan Kettering Cancer Center	High affinity anti-GD2 antibodies
AR097306A1 (es)	2013-08-20	2016-03-02	Merck Sharp & Dohme	Modulación de la inmunidad tumoral
CN105277638A (zh) *	2014-07-22	2016-01-27	沈鹤霄	一种单克隆抗体IgG质谱测序方法
JO3663B1 (ar)	2014-08-19	2020-08-27	Merck Sharp & Dohme	الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016196178A1 (en) *	2015-05-29	2016-12-08	Merck Sharp & Dohme Corp.	Combination of an anti-il-10 antibody and a cpg-c type oligonucleotide for treating cancer
EP3892284B1 (de)	2015-05-29	2024-05-22	Merck Sharp & Dohme LLC	Kombination aus einem pd-1-antagonist und cpg-c-typ-oligonukleotid zur behandlung von krebs
CA3132021C (en)	2015-11-18	2024-03-12	Merck Sharp & Dohme Corp.	Pd1 and/or lag3 binders
JP7000322B2 (ja)	2015-12-16	2022-02-04	メルク・シャープ・アンド・ドーム・コーポレーション	抗ｌａｇ３抗体および抗原結合性フラグメント
EP3394099A4 (de) *	2015-12-22	2019-11-27	Merck Sharp & Dohme Corp.	Formulierungen von manipulierten anti-il-10-antikörpern
RU2019138507A (ru)	2017-05-02	2021-06-02	Мерк Шарп И Доум Корп.	Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3079076A1 (en)	2017-10-18	2019-04-25	Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus	Methods and compounds for improved immune cell therapy
EP3768725A4 (de) *	2018-03-20	2021-06-02	Wuxi Biologics Ireland Limited	Neuartige anti-tim-3-antikörper
CN113056482A (zh)	2018-10-18	2021-06-29	默沙东公司	抗rsv抗体的制剂及其使用方法
CN120842406A (zh)	2018-10-31	2025-10-28	默沙东有限责任公司	抗人pd-1抗体晶体及其使用方法
KR20210089215A (ko)	2018-11-07	2021-07-15	머크 샤프 앤드 돔 코포레이션	항-lag3 항체 및 항-pd-1 항체의 공동-제제
WO2021072225A1 (en) *	2019-10-09	2021-04-15	Rush University Medical Center	Modulating interleukin-10 signaling to boost healing in diabetic wounds
CN116997359A (zh)	2020-11-18	2023-11-03	阿斯利康(瑞典)有限公司	类固醇节制
CN118043349B (zh) *	2021-06-11	2024-11-15	丰华生物有限公司	一种人源化抗人GPVI单克隆抗体Fab片段及其应用
WO2024091417A1 (en) *	2022-10-24	2024-05-02	Merck Sharp & Dohme Llc	Human hyaluronidase 1 mutants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154598B (nl)	1970-11-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3939350A (en)	1974-04-29	1976-02-17	Board Of Trustees Of The Leland Stanford Junior University	Fluorescent immunoassay employing total reflection for activation
US3996345A (en)	1974-08-12	1976-12-07	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en)	1978-04-05	1981-07-07	Syva Company	Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4366241A (en)	1980-08-07	1982-12-28	Syva Company	Concentrating zone method in heterogeneous immunoassays
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0438310A1 (de)	1990-01-19	1991-07-24	Merck & Co. Inc.	Verfahren zur Herstellung von rekombinanten Immunoglobulinen
US6018036A (en)	1990-06-29	2000-01-25	Schering Corporation	Nucleic acids encoding cytokine synthesis inhibitory factor (Interleukin-10)
ATE255131T1 (de) *	1991-06-14	2003-12-15	Genentech Inc	Humanisierter heregulin antikörper
PT600970E (pt) *	1991-08-06	2000-05-31	Schering Corp	Utilizacao de analogos ou antagonistas da interleucina-10 para tratar toxicidade induzida por endotoxinas ou superantigenios
DE69233528T2 (de)	1991-11-25	2006-03-16	Enzon, Inc.	Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
WO1994004180A2 (en) *	1992-08-20	1994-03-03	Schering Corporation	Novel uses of il-4 and/or il-10, and antibodies against the same
DE19529026C2 (de) *	1995-07-28	1997-06-19	Robert Sabat	Monoklonale Antikörper gegen humanes Interleukin-10
EP1261376A1 (de) *	2000-01-27	2002-12-04	Genetics Institute, LLC	Antikörper gegen ctla4(cd152), sie enthaltende konjugate und ihre verwendung
TWI255272B (en) *	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
MXPA05000511A (es) *	2001-07-12	2005-09-30	Jefferson Foote	Anticuepros super humanizados.
EP1441766B1 (de) *	2001-10-16	2011-09-14	MacroGenics West, Inc.	An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
ATE435239T1 (de) *	2002-03-29	2009-07-15	Schering Corp	Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen

2004
- 2004-11-08 AR ARP040104114A patent/AR046833A1/es active IP Right Grant
- 2004-11-08 WO PCT/US2004/037013 patent/WO2005047324A2/en not_active Ceased
- 2004-11-08 PE PE2008001585A patent/PE20090047A1/es not_active Application Discontinuation
- 2004-11-08 PE PE2004001085A patent/PE20050925A1/es active IP Right Grant
- 2004-11-08 PE PE2008001584A patent/PE20090046A1/es not_active Application Discontinuation
- 2004-11-09 RS RSP-2009/0439A patent/RS51180B/sr unknown
- 2004-11-09 HR HR20090517T patent/HRP20090517T1/xx unknown
- 2004-11-09 CA CA2812856A patent/CA2812856A1/en not_active Abandoned
- 2004-11-09 JP JP2006539809A patent/JP4762148B2/ja not_active Expired - Lifetime
- 2004-11-09 KR KR1020127001612A patent/KR20120023858A/ko not_active Ceased
- 2004-11-09 DE DE602004022855T patent/DE602004022855D1/de not_active Expired - Lifetime
- 2004-11-09 EP EP09010836A patent/EP2128175A1/de not_active Ceased
- 2004-11-09 CN CN200480040148A patent/CN100595212C/zh not_active Expired - Lifetime
- 2004-11-09 PL PL04810674T patent/PL1694705T3/pl unknown
- 2004-11-09 ES ES04810674T patent/ES2329907T3/es not_active Expired - Lifetime
- 2004-11-09 EP EP04810674A patent/EP1694705B1/de not_active Expired - Lifetime
- 2004-11-09 CN CN2010100045818A patent/CN102010471A/zh active Pending
- 2004-11-09 SG SG200905318-2A patent/SG155205A1/en unknown
- 2004-11-09 CA CA2545255A patent/CA2545255C/en not_active Expired - Lifetime
- 2004-11-09 US US10/985,584 patent/US20050101770A1/en not_active Abandoned
- 2004-11-09 EP EP10013136A patent/EP2292661A3/de not_active Withdrawn
- 2004-11-09 DK DK04810674T patent/DK1694705T3/da active
- 2004-11-09 NZ NZ546632A patent/NZ546632A/en not_active IP Right Cessation
- 2004-11-09 EP EP09010835A patent/EP2123678A1/de not_active Withdrawn
- 2004-11-09 PT PT04810674T patent/PT1694705E/pt unknown
- 2004-11-09 SI SI200431289T patent/SI1694705T1/sl unknown
- 2004-11-09 WO PCT/US2004/037518 patent/WO2005047326A2/en not_active Ceased
- 2004-11-09 KR KR1020127001620A patent/KR20120025618A/ko not_active Abandoned
- 2004-11-09 AU AU2004290044A patent/AU2004290044B2/en not_active Expired
- 2004-11-09 AT AT04810674T patent/ATE440867T1/de active
2006
- 2006-05-09 ZA ZA200603681A patent/ZA200603681B/xx unknown
- 2006-05-09 IL IL175523A patent/IL175523A/en active IP Right Grant
- 2006-05-10 KR KR1020067009074A patent/KR101175055B1/ko not_active Expired - Lifetime
- 2006-06-09 NO NO20062672A patent/NO20062672L/no not_active Application Discontinuation
2007
- 2007-01-12 US US11/623,006 patent/US7662379B2/en not_active Expired - Lifetime
2009
- 2009-10-20 CY CY20091101088T patent/CY1110557T1/el unknown
- 2009-12-10 IL IL202682A patent/IL202682A0/en active IP Right Grant
- 2009-12-10 IL IL202681A patent/IL202681A/en active IP Right Grant
- 2009-12-17 AR ARP090104950A patent/AR074779A2/es unknown
- 2009-12-17 AR ARP090104951A patent/AR074780A2/es not_active Application Discontinuation
2010
- 2010-02-05 US US12/701,386 patent/US8226947B2/en not_active Expired - Lifetime
- 2010-11-30 JP JP2010267845A patent/JP2011087590A/ja not_active Withdrawn
- 2010-11-30 JP JP2010267846A patent/JP2011062211A/ja not_active Withdrawn
2011
- 2011-02-14 AU AU2011200606A patent/AU2011200606B2/en not_active Ceased
2012
- 2012-07-19 US US13/553,554 patent/US8624013B2/en not_active Expired - Fee Related
2013
- 2013-07-24 JP JP2013153356A patent/JP2014014361A/ja not_active Withdrawn
- 2013-12-23 US US14/138,486 patent/US20140112919A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US8624013B2 (en)	2014-01-07
CN1906213A (zh)	2007-01-31
WO2005047326A3 (en)	2005-12-22
NZ546632A (en)	2009-07-31
US20120282253A1 (en)	2012-11-08
US7662379B2 (en)	2010-02-16
US8226947B2 (en)	2012-07-24
AR046833A1 (es)	2005-12-28
IL202681A (en)	2011-10-31
EP1694705B1 (de)	2009-08-26
JP2011087590A (ja)	2011-05-06
JP4762148B2 (ja)	2011-08-31
PE20090046A1 (es)	2009-01-26
CA2812856A1 (en)	2005-05-26
JP2014014361A (ja)	2014-01-30
KR101175055B1 (ko)	2012-08-22
EP2128175A1 (de)	2009-12-02
HK1087722A1 (en)	2006-10-20
AR074780A2 (es)	2011-02-09
ES2329907T3 (es)	2009-12-02
AU2004290044B2 (en)	2010-11-18
AU2011200606A1 (en)	2011-03-03
KR20060120093A (ko)	2006-11-24
CA2545255A1 (en)	2006-05-05
RS51180B (sr)	2010-10-31
KR20120023858A (ko)	2012-03-13
US20050101770A1 (en)	2005-05-12
JP2011062211A (ja)	2011-03-31
PL1694705T3 (pl)	2010-02-26
AU2011200606B2 (en)	2012-05-10
AU2004290044A1 (en)	2005-05-26
CN102010471A (zh)	2011-04-13
US20100203049A1 (en)	2010-08-12
JP2008500020A (ja)	2008-01-10
AR074779A2 (es)	2011-02-09
PE20050925A1 (es)	2005-11-29
NO20062672L (no)	2006-06-09
EP2292661A2 (de)	2011-03-09
IL175523A (en)	2011-01-31
SI1694705T1 (sl)	2010-01-29
IL202681A0 (en)	2010-06-30
US20140112919A1 (en)	2014-04-24
IL175523A0 (en)	2006-09-05
ZA200603681B (en)	2010-01-27
CN100595212C (zh)	2010-03-24
KR20120025618A (ko)	2012-03-15
CY1110557T1 (el)	2015-04-29
US20070178097A1 (en)	2007-08-02
PT1694705E (pt)	2009-11-30
HRP20090517T1 (hr)	2009-10-31
EP2123678A1 (de)	2009-11-25
PE20090047A1 (es)	2009-01-26
DK1694705T3 (da)	2009-12-07
WO2005047324A2 (en)	2005-05-26
EP2292661A3 (de)	2011-06-22
EP1694705A2 (de)	2006-08-30
WO2005047326A2 (en)	2005-05-26
DE602004022855D1 (de)	2009-10-08
IL202682A0 (en)	2010-06-30
CA2545255C (en)	2013-06-25
ATE440867T1 (de)	2009-09-15

Publication	Publication Date	Title
WO2005047326A3 (en)	2005-12-22	Interleukin-10 antibodies
IL195338A0 (en)	2011-08-01	Optimized fc variants and methods for their generation
WO2004001019A3 (en)	2004-08-05	Novel nanoparticles and use thereof
ZA200409186B (en)	2005-10-26	Specific antibodies to amyloid beta peptide, pahrmaceutical compositions and methods of use thereof.
WO2006137934A3 (en)	2009-03-05	Purposeful movement of human migratory cells away from an agent source
WO2003068821A3 (en)	2005-01-20	Anti-cd20 antibodies and fusion proteins thereof and methods of use
EP1461081A4 (de)	2006-05-17	Anti-cd45rb-antikörper zur verwendung bei der behandlung von autoimmunkrankheiten und transplantatabstossung
WO2004035742A3 (en)	2005-03-10	Sets of digital antibodies directed against short epitopes, and methods using same
SG166090A1 (en)	2010-11-29	Il-13 binding agents
MX337423B (es)	2016-03-04	Antagonistas anti-beta7 humanizados y usos para los mismos.
WO2004007679A3 (en)	2004-10-14	Dendritic cell pontentiation
PL1732588T3 (pl)	2009-12-31	Modulowanie NKG2D
TW200606177A (en)	2006-02-16	Glycoprotein VI antibodies and methods thereof
WO2001016114A3 (en)	2001-08-02	Heterocyclic compounds and methods for modulating cxcr3 function
WO2003057856A3 (en)	2005-12-22	Dominant negative proteins and methods thereof
WO2005046597A3 (en)	2005-11-03	Antibodies to cd44 glycoforms and uses thereof
WO2005023302A3 (en)	2005-04-28	Anti-cd20 therapy of ocular disorders
EP1285577A4 (de)	2007-05-09	Chimäre maus, deren immunsystem mithilfe menschlicher cd34-positiver zellen erzeugt ist, und ihre verwendung(26.11.01)
WO2002072807A3 (en)	2003-11-20	Chimeric metal-binding peptides with nuclease activity
TW200605786A (en)	2006-02-16	Dermally applicable liquid formulations for controlling parasitic arthropods on animals
WO2005009366A3 (en)	2005-07-28	Restoring vascular function
UA94211C2 (ru)	2011-04-26	Выделенное полностью человеческое моноклональное cd3 антитело
WO2005040339A3 (en)	2006-12-21	Aptamers to human epidermal growth factor receptor-3
SG146640A1 (en)	2008-10-30	Isolated photoprotein mtclytin, and use thereof
MY142401A (en)	2010-11-30	Materials and methods for improving shellfish heatlh, immunity and growth